GLP1R and type 2 diabetes mellitus: Since both metformin (Kim, Yu et al. 2021; Noren Hooten et al. 2016) and GLP1R‐agonists (Zhang et al. 2019) have been associated with possible effects on senescence and aging, we also examined whether T2DM participants on these drugs differed in terms of senescence or other markers as compared to those not taking them.